NCT04392830

A Study to Investigate the Safety, Tolerability, Pharmacokinetics of ALZ002 DS in Healthy Volunteers

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study, to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses (SAD-MAD) of ALZ002 DS in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: AnnJi Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single-ascending and multiple-ascending doses of ALZ002 DS.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	ALZ002 DS	Administered orally
DRUG	Placebo	Administered orally

Timeline

• Start date: 2020-05-11
• Primary completion: 2021-04-28
• Completion: 2021-06-15
• First posted: 2020-05-19
• Last updated: 2021-08-18

Locations

1 site across 1 country: Australia

Regulatory

• FDA-regulated drug study